Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460)

:0460

0460

Sihuan Pharmaceutical Holdings Group

RESEARCH TOOLSreports

Want to see HK:0460 full AI Analyst Report?

Sihuan Pharmaceutical Holdings Group (0460) Price & Analysis

1 Followers

0460 Stock Chart & Stats

HK$1.32

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$1.32

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.79 - HK$1.92

Previous CloseN/A

Volume8.01M

Average Volume (3M)37.54M

Market Cap

HK$10.08B

Enterprise ValueHK$5.71B

Total Cash (Recent Filing)HK$4.10B

Total Debt (Recent Filing)HK$912.57M

Price to Earnings (P/E)56.1

Beta1.04

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.87%

Share Statistics

EPS (TTM)0.02

Shares Outstanding9,329,999,000

10 Day Avg. Volume24,963,024

30 Day Avg. Volume37,542,935

Financial Highlights & Ratios

PEG Ratio-0.30

Price to Book (P/B)1.72

Price to Sales (P/S)3.85

P/FCF Ratio-46.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$2.00

Price Target Upside51.52% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.07

Revenue Forecast (FY)HK$3.59B

Bulls Say, Bears Say

Bulls Say

Revenue ReboundA 21.6% revenue rebound and return to positive net income indicate renewed commercial traction in core therapeutic areas. Durable revenue growth over several quarters supports reinvestment in R&D and sales coverage, strengthening medium-term market position and product momentum.

High Gross MarginsSustained 65–70% gross margins reflect strong product-level pricing power, likely from branded or specialty lines. High gross margins give the company earnings leverage versus peers, helping absorb SG&A or R&D spending and preserving profitability through industry price pressure.

Manageable LeverageA low and improving debt-to-equity ratio provides financial flexibility and a buffer against shocks, lowering interest burden and refinancing risk. This balance-sheet strength supports funding operations, acquisitions, or product investment without excessive leverage over the medium term.

Bears Say

Weak Cash GenerationNegative operating and free cash flow amid reported profits signals quality-of-earnings concerns and potential working-capital stress. Persistently weak cash generation can constrain investment, force external financing, and reduce resilience to regulatory or market shocks over the coming months.

Inconsistent Free Cash FlowFrequent FCF volatility across multiple years points to structural swings from working capital or uneven capex cycles. This unpredictability undermines capital allocation planning, raises refinancing probability in weak periods, and limits reliable shareholder returns or sustained R&D funding.

Earnings Volatility & Low ROEHistoric large losses, intermittent negative margins, and low ROE indicate earnings are not yet consistently translating into shareholder returns. Persistent earnings volatility reduces predictability of profitability, complicates strategic planning and investor confidence over the medium term.

Sihuan Pharmaceutical Holdings Group News

Sihuan Pharmaceutical Launches Share Buyback as Medical Aesthetics Surge Drives Return to Profit

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Sihuan Pharmaceutical Holdings Group has announced a...

3d ago

Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical Holdings Group has strengthened its...

8d ago

Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong

The latest update is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical announced that its...

9d ago

Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical has reported that...

30d ago

Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial

An announcement from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical announced that preliminary...

1M ago

Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib

The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical’s non-wholly-owned subsidiary Xuanzhu...

1M ago

Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Sihuan Pharmaceutical Holdings Group announced that its...

1M ago

Sihuan Unit Wins China Nod for Phase III Anaprazole Trial in H. pylori

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has provided an update. Sihuan Pharmaceutical’s subsidiary Xuanzhu Biopharm has received...

1M ago

Sihuan Subsidiary Xuanzhu Biopharm Clears CSRC Filing for Major H-Share Conversion

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical Holdings Group announced...

1M ago

Sihuan’s Xuanzhu Biopharm Licenses Two Oncology Drugs to Boston Oncology for MENA Markets

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an announcement. Xuanzhu Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical...

1M ago

0460 FAQ

What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.79 and its highest was HK$1.92 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?

Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$10.08B.

When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?

Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.

How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.009 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.009.

Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?

Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 0.87%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here

What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?

Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?

Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.009 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.493%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?

Currently, no hedge funds are holding shares in HK:0460

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sihuan Pharmaceutical Holdings Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

3.49%

Trailing 12-Months

Asset Growth

15.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.

Sihuan Pharmaceutical Holdings Group (0460) Earnings & Revenues

Historic Earnings Reports

0460 Stock 12 Month Forecast

Average Price Target

HK$2.00

▲(51.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"HK$0","1":"HK$1","2":"HK$2","3":"HK$3","-1":"-HK$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.3261538461538462,1.3823076923076922,1.4384615384615385,1.4946153846153847,1.5507692307692307,1.606923076923077,1.6630769230769231,1.7192307692307693,1.7753846153846153,1.8315384615384616,1.8876923076923076,1.9438461538461538,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.3261538461538462,1.3823076923076922,1.4384615384615385,1.4946153846153847,1.5507692307692307,1.606923076923077,1.6630769230769231,1.7192307692307693,1.7753846153846153,1.8315384615384616,1.8876923076923076,1.9438461538461538,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.27,1.3261538461538462,1.3823076923076922,1.4384615384615385,1.4946153846153847,1.5507692307692307,1.606923076923077,1.6630769230769231,1.7192307692307693,1.7753846153846153,1.8315384615384616,1.8876923076923076,1.9438461538461538,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.715,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.933,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.102,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.291,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.509,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >